0001209191-17-062760.txt : 20171128 0001209191-17-062760.hdr.sgml : 20171128 20171128192657 ACCESSION NUMBER: 0001209191-17-062760 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171125 FILED AS OF DATE: 20171128 DATE AS OF CHANGE: 20171128 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LEE ANN L. CENTRAL INDEX KEY: 0001723629 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36781 FILM NUMBER: 171226553 MAIL ADDRESS: STREET 1: 400 DEXTER AVENUE NORTH STREET 2: SUITE 1200 CITY: SEATTLE STATE: WA ZIP: 98109 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Juno Therapeutics, Inc. CENTRAL INDEX KEY: 0001594864 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 463656275 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 DEXTER AVENUE NORTH, SUITE 1200 CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 2065821600 MAIL ADDRESS: STREET 1: 400 DEXTER AVENUE NORTH, SUITE 1200 CITY: SEATTLE STATE: WA ZIP: 98109 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-11-25 0 0001594864 Juno Therapeutics, Inc. JUNO 0001723629 LEE ANN L. C/O 400 DEXTER AVENUE NORTH SUITE 1200 SEATTLE WA 98109 0 1 0 0 EVP, Technical Operations Common Stock 2017-11-25 4 A 0 35004 0.00 A 35004 D Common Stock 2017-11-25 4 A 0 35000 0.00 A 70004 D Stock Opton (Right to Buy) 62.85 2017-11-25 4 A 0 152900 0.00 A 2027-11-24 Common Stock 152900 152900 D Represents a restricted stock award ("RSA") granted pursuant to the 2014 Equity Incentive Plan. 50% of the shares subject to the RSA shall vest on each anniversary of November 25, 2017. Represents a RSA granted pursuant to the 2014 Equity Incentive Plan. The RSA will become eligible to vest based on the achievement of certain performance goals as follows, subject to the reporting person remaining a service provider to the Issuer through the applicable vesting date: Up to 21,000 shares will become eligible to vest based on the first approval by the U.S. Food & Drug Administration (the "FDA") of JCAR017 in any indication within certain designated timeframes (the "JCAR017 Milestone"). 50% of the shares that become eligible to vest upon the achievement of the JCAR017 Milestone will vest immediately upon such achievement. The remaining 50% of shares that become eligible to vest upon the achievement of the JCAR017 Milestone will vest on the one year anniversary of the date of such achievement. Up to 9,000 shares will vest based upon the first approval by the FDA of JCARH125 in any indication within certain designated timeframes. 25% of the shares subject to the option shall vest and become exercisable on November 25, 2018 and 1/48th of the shares subject to the option shall vest and become exercisable monthly thereafter. /s/ Zachary D. Hale, attorney-in-fact 2017-11-28